glp-1 種類 風靡全球「瘦瘦針」Q & A 不只降血糖、減重， 還可治療脂肪肝？！ GLP-1 是什麼？ 減重藥效益、副作用與停藥復胖風險｜潮健康

Andrew Gostine Andrew Gostine, MD, MBA, is an accomplished healthcare professional, passionate about leveraging artificial intelligence in the clinical setting

Clinical eligibility for GLP-1 drugs was determined using BMI and the following comorbidities as specified in NHIS: coronary heart disease, prior stroke, prior heart attack, angina, high blood pressure, and high cholesterol

As in the shorter-term studies, DPP-4 inhibition was well-tolerated with no increased risk of hypoglycaemia, despite the improvement in glycaemic control, and the overall adverse event profile was similar in both arms of the study

Skipping doses reduces semaglutide's appetite-suppressing effects and can interrupt your weight loss progress

PowerLab software (8SP, AD Instruments, Colorado Spring, CO) was used to record mean arterial pressure (MAP) and heart rate (HR), simultaneously

IP glucose tolerance tests (IPGTT) were performed the same way, starting with an IP administration of glucose at 1 g/kg ( n = 6 RD and n = 7 WD)